Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients;Consecuencias clínicas y económicas de la combinación de metformina con inhibidores de la dipeptidilpeptidasa en pacientes con diabetes tipo 2

Revista Clinica Espanola

Volumn 213, Issue 8, 2013, Pages 377-384

  Sicras Mainar, A ^a   Roldan Suarez C ^b   Font Ramos, B ^b   Navarro Artieda, R ^c   Ibanez Nolla J ^a  

^a Badalona Serveis Assistencials SA   (Spain)

^b Health Outcomes Research   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Cardiovascular disease; Diabetes; DPPIV; Health care costs; Hypoglycemia; Metabolic control

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; METFORMIN; DIPEPTIDYL PEPTIDASE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COST; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; ECONOMICS; MULTICENTER STUDY;

AGED; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; RETROSPECTIVE STUDIES;

EID: 84886950696     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2013.06.003     Document Type: Article

References (26)

1. M. Mata, F. Antoñanzas, M. Tafalla, and P. Sanz El coste de la diabetes tipo 2 en España. El estudio CODE-2 Gac Sanit 16 2002 511 520
2. J.A. Ray, W.J. Valentine, K. Secnik, A.K. Oglesby, A. Cordony, and A. Gordois Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain Curr Med Res Opin 21 2005 1617 1629
3. P. González, E. Faure, del Castillo A Grupo de Trabajo para el Estudio del Coste de la Diabetes Cost of diabetes mellitus in Spain Med Clin (Barc) 127 2006 776 784
4. J. Rosado Martín, Martínez López MÁ, T. Mantilla Morató, I. Dujovne Kohan, F.J. Palau Cuevas, R. Torres Jiménez MAPA Prevalence of diabetes in an adult population in the region of Madrid (Spain). The Madrid Cardiovascular Risk study Gac Sanit 26 2012 243 250
5. F. Soriguer, A. Goday, A. Bosch-Comas, E. Bordiú, A. Calle-Pascual, and R. Carmena Prevalence of diabetes mellitus and impaired glucose regulation in Spain: The Di@betes Study Diabetologia 55 2012 88 93
6. E. Menéndez Torre, J. Lafita Tejedor, S. Artola Menéndez, J. Millán Núñez-Cortés, A. Alonso García, M. Puig Domingo Sociedad Española de Diabetes Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes Rev Clin Esp 211 2011 147 155
7. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
8. Puigdevall Gallego V., C. Laudo Pardos, M.J. del Río Mayor, and A. Velasco Martín New drugs for the treatment of type-2 diabetes Rev Clin Esp 200 2000 151 156
9. A. Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, M. Woodward The ADVANCE collaborative group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
10. D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferrannini, R.R. Colman, and R. Sherwin Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
11. R.C. Turner, C.A. Cull, V. Frighi, and R.R. Holman Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 281 1999 2005 2012
12. P.E. Wiedeman DPPIV inhibition: Promising therapy for the treatment of type 2 diabetes Prog Med Chem 45 2007 63 109
13. H. Lamberts, M. Wood, and Í.M. Hofmans-Okkes The Ínternational Classification of Primary Care in the European Community. With a multi-language layer 1993 Oxford University Press Oxford
14. WHO; 1991. The Anatomical Therapeutic Chemical Classification System.
15. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. Mackenzie A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation J Chronic Dis 40 1987 373 383
16. J.P. Weiner, B.H. Starfield, D.M. Steinwachs, and L.M. Mumford Development and application of a population-oriented measure of ambulatory care case-mix Med Care 29 1991 452 472
17. Instituto Nacional de Estadística 2010. Encuesta de costes laborales del año 2010 [consultado Sep 2012]. Disponible en: http://www.ine.es/infoine
18. S.G. Thompson, and J.A. Barber How should cost data in pragmatic randomised trials be analysed? BMJ 320 2000 1197 1200
19. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 1998 837 853
20. P. Gaede, H. Lund-Andersen, H.H. Parving, and O. Pedersen Effect of a multifactorial intervention on mortality and in type 2 diabetes N Engl J Med 358 2008 580 591
21. E. Márquez Contreras, N. Martell Claros, V. Gil Guillén, J.J. Casado Martínez, J.L. Martín de Pablos, J. Ferraro García Grupo de Trabajo sobre Cumplimiento de la Asociación de la Sociedad Española de Hipertensión Arterial y Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA) Therapeutic non-compliance with insulin in the treatment of diabetes mellitus 2 Aten Primaria 44 2012 74 81
22. J.A. Cramer, A. Benedict, N. Muszbek, A. Keskinaslan, and Z.M. Khan The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: A review Int J Clin Pract 62 2008 76 87
23. G. Jermendy, I. Wittmann, L. Nagy, Z. Kiss, G. Rokszin, and Z. Abonyi-Tóth Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus Med Sci Monit 18 2012 CR72 CR77
24. L. Breitscheidel, S. Stamenitis, F.W. Dippel, and O. Schöffski Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: A review paper J Med Econ 13 2010 8 15
25. H. Wild The economic rationale for adherence in the treatment of type 2 diabetes mellitus Am J Manag Care 18 Suppl 3 2012 S43 S48
26. S. Liu, Y. Zhao, J.M. Hempe, V. Fonseca, and L. Shi Economic burden of hypoglycemia in patients with Type 2 diabetes Expert Rev Pharmacoecon Outcomes Res 12 2012 47 51